NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

Oxyzyme and Iodozyme are chronic wound dressings that release iodine and oxygen onto the wound surface. They may be used on moderately exuding, non-exuding or dry wounds, and under compression therapy. The Oxyzyme dressing is intended for the treatment of non-infected or mildly infected wounds and the Iodozyme dressing may be used in the management of infected wounds.

Medtech Innovation Briefings provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence.

Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.

MIBs are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics.

Medtech Innovation Briefings are not NICE guidance. They differ in format, contain no judgement on the value of the technology and do not constitute a guidance recommendation.

NICE Medtech Innovation Briefings are commissioned by NHS England and produced in support of Innovation Health and Wealth.